NervGen Pharma (NASDAQ:NGEN) Stock Rating Upgraded by Wall Street Zen

NervGen Pharma (NASDAQ:NGEN) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Monday.

Several other equities analysts have also weighed in on the company. Weiss Ratings initiated coverage on NervGen Pharma in a report on Friday, April 24th. They set a “sell (d-)” rating for the company. Leerink Partners initiated coverage on NervGen Pharma in a research note on Monday, July 13th. They issued an “outperform” rating and a $10.00 target price on the stock. Zacks Research raised NervGen Pharma to a “hold” rating in a research report on Wednesday, April 29th. HC Wainwright upgraded NervGen Pharma to a “strong-buy” rating in a research note on Tuesday, April 28th. Finally, TD Cowen initiated coverage on NervGen Pharma in a report on Thursday, June 11th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $14.00.

NervGen Pharma Trading Up 2.9%

Shares of NGEN stock opened at $1.78 on Monday. The company has a market capitalization of $143.52 million and a price-to-earnings ratio of -19.78. NervGen Pharma has a 52 week low of $1.59 and a 52 week high of $6.30. The stock has a 50-day moving average of $2.19.

NervGen Pharma (NASDAQ:NGEN) last released its earnings results on Friday, May 15th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02).

NervGen Pharma Company Profile

NervGen Pharma Corp. is a clinical-stage biotechnology company focused on developing therapies to promote nerve repair and restore neurological function following injury or disease. The company advances regenerative approaches intended to address damage in the central and peripheral nervous systems, pursuing programs that aim to translate preclinical repair concepts into human treatments.

The company’s lead investigational candidate is NVG-291, which is being evaluated in clinical studies for indications that include spinal cord injury, neuropathic conditions and neurodegenerative disease settings.